Effects of once-daily versus twice-daily darunavir/ritonavir on lipid parameters at week 48 in treatment-experienced, HIV-1-infected patients with no darunavir resistance-associated mutations (RAMs) in the ODIN study

被引：0
|
作者：
Arribas, J. [1 ]
Arathoon, E. [2 ]
Gonsalez, C. R. [3 ]
Latiff, G. H. [4 ]
Van De Casteele, T. [5 ]
De Doncker, P. [5 ]
De La Rosa, G. [6 ]
Spinosa-Guzman, S. [5 ]
机构：
[1] Hosp Univ La Paz, IdiPAZ, Madrid, Spain
[2] Clin Familiar Luis Angel Garcia, Guatemala City, Guatemala
[3] Univ Sao Paulo, Hosp Clin, Fac Med, Pinheiros, Brazil
[4] Maxwell Ctr, Durban, South Africa
[5] Tibotec BVBA, Beerse, Belgium
[6] Tibotec Therapeut, Titusville, NJ USA
来源：
ANTIVIRAL THERAPY | 2010年 / 15卷
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
引用
收藏
页码：A59 / A60
页数：2
相关论文
共 50 条
  • [11] SOLO:: 48-week efficacy and safety comparison of once-daily fosamprenavir/ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients
    Gathe, JC
    Ive, P
    Wood, R
    Schürmann, D
    Bellos, NC
    DeJesus, E
    Gladysz, A
    Garris, C
    Yeo, J
    AIDS, 2004, 18 (11) : 1529 - 1537
  • [12] Once-daily boosted darunavir as a new therapeutic option for treatment-experienced HIV-infected patients
    Dabrowska, Magdalena M.
    Kozlowska, Joanna
    HIV & AIDS REVIEW, 2011, 10 (03): : 54 - 55
  • [13] Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis
    Mills, Anthony M.
    Nelson, Mark
    Jayaweera, Dushyantha
    Ruxrungtham, Kiat
    Cassetti, Isabel
    Girard, Pierre-Marie
    Workman, Cassy
    Dierynck, Inge
    Sekar, Vanitha
    Abeele, Carline Vanden
    Lavreys, Ludo
    AIDS, 2009, 23 (13) : 1679 - 1688
  • [14] Similar Safety and Efficacy of Once- and Twice-Daily Lopinavir/Ritonavir Tablets in Treatment-Experienced HIV-1-Infected Subjects at 48 Weeks
    Zajdenverg, Roberto
    Podsadecki, Thomas J.
    Badal-Faesen, Sharlaa
    Andrade-Villanueva, Jaime
    Gathe, Joseph
    Mingrone, Horacio
    Fredrick, Linda M.
    Gaultier, Isabelle A.
    Woodward, W. Chris
    Bernstein, Barry M.
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2010, 54 (02) : 143 - 151
  • [15] Effect of Baseline Characteristics on the Efficacy and Safety of Once-Daily Darunavir/Ritonavir in HIV-1-Infected, Treatment-Naive ARTEMIS Patients at Week 96
    Fourie, Jan
    Flamm, Jason
    Rodriguez-French, Amalia
    Kilby, Don
    Domingo, Pere
    Lazzarin, Adriano
    Ballesteros, Juan
    Sosa, Nestor
    Van De Casteele, Tom
    DeMasi, Ralph
    Spinosa-Guzman, Sabrina
    Layreys, Ludo
    HIV CLINICAL TRIALS, 2011, 12 (06): : 313 - 322
  • [16] Pharmacokinetic Study of Dual Therapy With Raltegravir 400 mg Twice Daily and Darunavir/Ritonavir 800/100 mg Once Daily in HIV-1-Infected Patients
    Martinez-Rebollar, Maria
    Munoz, Ana
    Perez, Inaki
    Hidalgo, Susana
    Brunet, Merce
    Laguno, Montserrat
    Gonzalez, Ana
    Calvo, Marta
    Lonca, Montserrat
    Blanco, Jose Luis
    Martinez, Esteban
    Maria Gatell, Jose
    Mallolas, Josep
    THERAPEUTIC DRUG MONITORING, 2013, 35 (04) : 552 - 556
  • [17] Study of Once-Daily Versus Twice-Daily Fosamprenavir plus Ritonavir Administered with Abacavir/Lamivudine Once Daily in Antiretroviral-Naive HIV-1-Infected Adult Subjects
    Carosi, G.
    Lazzarin, A.
    Stellbrink, H.
    Moyle, G.
    Rugina, S.
    Staszewski, S.
    Givens, N.
    Ross, L.
    Granier, C.
    Ait-Khaled, M.
    Leather, D.
    Nichols, W. G.
    HIV CLINICAL TRIALS, 2009, 10 (06): : 356 - 367
  • [18] Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naive patients in the ARTEMIS trial
    Orkin, C.
    DeJesus, E.
    Khanlou, H.
    Stoehr, A.
    Supparatpinyo, K.
    Lathouwers, E.
    Lefebvre, E.
    Opsomer, M.
    Van de Casteele, T.
    Tomaka, F.
    HIV MEDICINE, 2013, 14 (01) : 49 - 59
  • [19] Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and erntricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study
    Molina, Jean-Michel
    Andrade-Villanueva, Jaime
    Echevarria, Juan
    Chetchotisakd, Ploenchan
    Corral, Jorge
    David, Neal
    Moyle, Graeme
    Mancini, Marco
    Percival, Lisa
    Yang, Rong
    Thiry, Alexandra
    McGrath, Donnie
    LANCET, 2008, 372 (9639): : 646 - 655
  • [20] Pharmacokinetics and tolerability of once- versus twice-daily lopinavir/ritonavir treatment in HIV-1-infected children
    la Porte, Charles
    van Heeswijk, Rolf
    Mitchell, Charles D.
    Zhang, Guijun
    Parker, Jackie
    Rongkavilit, Chokechai
    ANTIVIRAL THERAPY, 2009, 14 (04) : 603 - 606
12345